Metrics as of 10/15/2026, 02:13 PM (Berlin time), refresh in progress.
Molecular Partners Stock
Molecular Partners AG
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Switzerland
- CEO
- Patrick Amstutz
- Employees
- 134
- Market cap
- CHF119 M
- IPO
- 03/03/2015
Molecular Partners AG is a clinical-stage biopharmaceutical firm dedicated to discovering, developing, and bringing to market novel therapeutic proteins. Leveraging its proprietary DARPin® platform, the company is advancing a diverse pipeline of product candidates. A key asset is Abicipar, a DARPin-based treatment…
Company description based on the data provider's company data, AI-assisted, created on 15/10/2026. Not investment advice.
Molecular Partners stock: price history
1D
+1.0%
1W
-6.0%
1M
-7.7%
6M
-4.6%
YTD
-8.3%
1Y
+7.2%
2Y
-26.0%
5Y
-83.0%
10Y
-87.1%
Next earnings date
Next earnings date
29/10/2026 (in 12 days)
Volatility around earnings
~8% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vsqueeze-release-v1.0 on 14/10/26. Not a buy or sell signal.Beta
What does this mean?
Volatility squeeze
BearishPrice swings had compressed unusually tight beforehand (volatility near a low) and are now releasing into a stronger move. Technical analysis views such tight phases as often preceding a bigger move.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Molecular Partners
Analyst assessment of Molecular Partners
0
STRONG BUY
0
BUY
2
HOLD
0
SELL
0
STRONG SELL
2
TOTAL · Hold
As of: 29/08/2022
Molecular Partners stock metrics
P/E
-2.29
P/B
2.06
EV/EBITDA
-1.1
RETURN ON EQUITY
-23.2%
NET MARGIN
0.0%
DEBT/EQUITY
0.05
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
82.9%
FLOAT SHARES
31,740,413
AVG. DAILY VOLUME (30D)
10,428
Comparable stocks
Frequently asked questions about Molecular Partners stock
What does Molecular Partners do?
Molecular Partners AG is a company in the Healthcare sector, Biotechnology industry, headquartered in Switzerland.
The CEO is Patrick Amstutz, the company employs around 134 people.
The IPO was on 03/03/2015; the stock trades on SIX under the ticker MOLN.SW.
What do analysts say about Molecular Partners stock?
2 analysts rate the stock, the consensus is Hold (as of 29/08/2022).
This is an external assessment, not a statement by Market Jury.
When does Molecular Partners report next?
The next earnings date is 29/10/2026.
Around past earnings, price swings were roughly 8% stronger than usual.
Does Molecular Partners pay a dividend?
No, Molecular Partners currently does not pay a dividend.
Which stocks are comparable to Molecular Partners?
Comparable stocks include BeOne Medicines, Pharvaris, Idorsia, Basilea Pharmaceutica, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and argenx.
How can I get Molecular Partners stock analyzed?
Clicking "Analyze stock" lets five strategies assess Molecular Partners against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.